Long-term immunosuppressive treatment of serpiginous choroiditis

被引:37
作者
Akpek, EK
Baltatzis, S
Yang, J
Foster, CS
机构
[1] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ocular Immunol & Uveitis Serv, Boston, MA 02114 USA
[2] Univ Athens, Dept Ophthalmol, Athens, Greece
关键词
serpiginous choroiditis; long-term treatment; immunosuppression;
D O I
10.1076/ocii.9.3.153.3962
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: To determine the efficacy of immunosuppressive treatment in serpiginous choroiditis. Design: The clinical courses were reviewed of six consecutive patients (12 eyes) with vision-threatening, steroid-dependent/resistant serpiginous choroiditis treated with a combination of immunosuppressive agents including azathioprine, cyclosporine, and cyclophosphamide. All patients underwent treatment for at least 12 months. Results: The follow-up period ranged from 17 to 105 months (mean 57, median 43). All patients were able to taper oral steroids. Five patients discontinued all immunosuppressive medications after a treatment period of 12 to 69 months (mean 39 months). Immunosuppressive treatment was continued in one patient at a 'low' maintenance dose. Ten eyes had improved visual acuities, while vision remained impaired in two due to macular scars. Recurrence was noted in two patients when an attempt was made to decrease the dose of immunosuppressive medication. Two patients experienced side effects which were reversed by decreasing the dose of the medications. Conclusion: Long-term immunosuppressive treatment appears to prolong remission and preserve vision in patients with serpiginous choroiditis.
引用
收藏
页码:153 / 167
页数:15
相关论文
共 55 条
[1]  
AKOVA YA, 1993, OPHTHALMOLOGY, V100, P1775
[2]  
ANDRASCH RH, 1978, ARCH OPHTHALMOL-CHIC, V96, P247
[3]  
BAER JC, 1989, OPHTHALMOLOGY S, V96, P128
[4]  
BLUMENKRANZ MS, 1982, ARCH OPHTHALMOL-CHIC, V100, P1773
[5]   LATE STAGE OF SERPIGINOUS (GEOGRAPHIC) CHOROIDITIS [J].
CHISHOLM, IH ;
GASS, JDM ;
HUTTON, WL .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1976, 82 (03) :343-351
[6]  
Cohen E, 1993, Ocul Immunol Inflamm, V1, P195, DOI 10.3109/09273949309085018
[7]   RENAL-FUNCTION AND BLOOD-PRESSURE IN PATIENTS RECEIVING LONG-TERM, LOW-DOSE CYCLOSPORINE THERAPY FOR IDIOPATHIC AUTOIMMUNE UVEITIS [J].
DERAY, G ;
BENHMIDA, M ;
LEHOANG, P ;
MAKSUD, P ;
AUPETIT, B ;
BAUMELOU, A ;
JACOBS, C .
ANNALS OF INTERNAL MEDICINE, 1992, 117 (07) :578-583
[8]   Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine [J].
Falkenhain, ME ;
Cosio, FG ;
Sedmak, DD .
TRANSPLANTATION, 1996, 62 (03) :364-370
[9]   WEGENERS GRANULOMATOSIS - PROSPECTIVE CLINICAL AND THERAPEUTIC EXPERIENCE WITH 85 PATIENTS FOR 21 YEARS [J].
FAUCI, AS ;
HAYNES, BF ;
KATZ, P ;
WOLFF, SM .
ANNALS OF INTERNAL MEDICINE, 1983, 98 (01) :76-85
[10]   RISK-FACTORS FOR CYCLOSPORINE-INDUCED NEPHROPATHY IN PATIENTS WITH AUTOIMMUNE-DISEASES [J].
FEUTREN, G ;
MIHATSCH, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (25) :1654-1660